Prevalence of oncogenic drivers in non-squamous NSCLC1,*
With the addition of KRAS G12C as one of the 10 actionable molecular biomarkers,†
nearly 45% of patients with NSCLC have an actionable oncogenic driver1,3
*Molecular alteration prevalence can vary slightly between different datasets and studies. Values in graph based on approximate molecular alteration frequencies from the AACR genie version 12.0 dataset (N=19,777). Participating institutions include academic centers in Western countries. This graph only includes alterations predictive of response to an FDA-approved drug in locally advanced or metastatic NSCLC.1
†As of December 1, 2022.
AACR, American Association for Cancer Research; ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B;
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET, mesenchymal epithelial transition; NSCLC, non-small cell lung cancer; NTRK, neurotrophic-tropomyosin receptor kinase; RET, rearranged during transfection; ROS1, rearrangement of the receptor tyrosine kinase 1.
LUMAKRAS is not a chemotherapy, immunotherapy, or TKI. It’s a highly selective‡ oral
inhibitor designed specifically for patients with a KRAS G12C mutation4,5
‡Cysteine proteome analysis of 6,451 peptides showed sotorasib only covalently engages with Cys12 of KRASG12C. Preclinical studies in 22 cell lines and xenograft models demonstrated that sotorasib does not inhibit KRAS wild-type or non–KRAS G12C lines/tumors.5
GDP, guanosine diphosphate; TKI, tyrosine kinase inhibitor.
Interstitial Lung Disease (ILD)/Pneumonitis
Most common adverse reactions
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Please see full Prescribing Information.